Loading…

Stage II colonic adenocarcinoma: a detailed study of pT4N0 with emphasis on peritoneal involvement and the role of tumour budding

Canney A L, Kevans D, Wang L M, Hyland J M P, Mulcahy H E, O’Donoghue D P, O’Sullivan J, Geraghty R & Sheahan K 
(2012) Histopathology 61, 488–496 Stage II colonic adenocarcinoma: a detailed study of pT4N0 with emphasis on peritoneal involvement and the role of tumour budding Aims:  Evaluation o...

Full description

Saved in:
Bibliographic Details
Published in:Histopathology 2012-09, Vol.61 (3), p.488-496
Main Authors: Canney, Aoife L, Kevans, David, Wang, Lai Mun, Hyland, John M P, Mulcahy, Hugh E, O'Donoghue, Diarmuid P, O'Sullivan, Jacintha, Geraghty, Robert, Sheahan, Kieran
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Canney A L, Kevans D, Wang L M, Hyland J M P, Mulcahy H E, O’Donoghue D P, O’Sullivan J, Geraghty R & Sheahan K 
(2012) Histopathology 61, 488–496 Stage II colonic adenocarcinoma: a detailed study of pT4N0 with emphasis on peritoneal involvement and the role of tumour budding Aims:  Evaluation of peritoneal involvement in colonic cancer (CC) can be difficult. We studied pT4N0 cancers and their association with pathological prognostic markers, including tumour budding. Method and results:  Tumours were classified as (i) at the peritoneal surface or free in the peritoneal cavity (pT4a subgroup n = 44); (ii) directly invading adjacent organ (pT4b subgroup n = 8); or (iii) showing inflammatory involvement of the peritoneum (pT4I subgroup n = 25). A published pT3N0 cohort was used to compare Stage II subgroups. Standard pathological markers including tumour budding were assessed. Elastin staining was performed in the pT4I subgroup. Seventy‐seven Stage II CCs met inclusion criteria. There was no significant difference in survival across subgroups. pT4b tumours were larger than pT4a tumours (P 
ISSN:0309-0167
1365-2559
DOI:10.1111/j.1365-2559.2012.04250.x